Clinical Trial Update: Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating adding bevacizumab to carboplatin-paclitaxel and pembrolizumab for pMMR TP53-mutated advanced or recurrent endometrial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Status: RECRUITING